Bolt Biotherapeutics (Bolt Biotherapeutics) Growth Rank : 0 (As of May. 01, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Growth Rank?

Bolt Biotherapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Bolt Biotherapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Bolt Biotherapeutics (Bolt Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (NAS:BOLT) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

6LP:Germany

Address

900 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.boltbio.com

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.

Executives

William P. Quinn	officer: Chief Financial Officer	SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Edgar Engleman	director	575 HIGH STREET, STE 201, PALO ALTO CA 94301
Vivo Capital Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Laura Berner	director	C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Brian O'callaghan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Frank D. Lee	director	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Kathleen Laporte	director
Miller Richard A Md	director	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Mahendra Shah	director	2250 HOLCOMBE BLVD, HOUSTON TX 77030
Grant Yonehiro	officer: Chief Business Officer	C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063
Randall C Schatzman	director, officer: Chief Executive Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
David Dornan	officer: Chief Scientific Officer	C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Edith A. Perez	officer: Chief Medical Officer	C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063